ReviewBirth defects research. Part C, Embryo today : reviews2009
DNA methylation of cancer genome.
Review in Birth defects research. Part C, Embryo today : reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 151 citations in OpenAlex.
- Review
- Can social adversity alter the epigenome, trigger oral disease, and affect future generations?Irish journal of medical science · 2024Review
- Article
- Virus-induced host genomic remodeling dysregulates gene expression, triggering tumorigenesis.Frontiers in cellular and infection microbiology · 2024Review
- Epigenetic Targets and Pathways Linked to SARS-CoV-2 Infection and Pathology.Microorganisms · 2023Review
- Identification of long non-coding RNA using single nucleotide epimutation analysis: a novel gene discovery approach.Cancer cell international · 2022Article
- Coronary artery disease and cancer: a significant resemblance.Medical oncology (Northwood, London, England) · 2022Review
- Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer.International journal of molecular sciences · 2022Review
- Review
- Preliminary Study on the Sequencing of Whole Genomic Methylation and Transcriptome-Related Genes in Thyroid Carcinoma.Cancers · 2022Article
- Tumor vessel co-option: The past & the future.Frontiers in oncology · 2022Review
- DNA Methylation Profiling of MYC, SMAD2/3 and DNMT3A in Colorectal Cancer.Oman medical journal · 2021Review
- [Peripheral bloodNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Unraveling the Wide Spectrum of Melanoma Biomarkers.Diagnostics (Basel, Switzerland) · 2021Review
- Identification of novel DNA hypermethylation of the adenylate kinase 5 promoter in colorectal adenocarcinoma.Scientific reports · 2021Article
- Review
- Epigenome Chaos: Stochastic and Deterministic DNA Methylation Events Drive Cancer Evolution.Cancers · 2021Review
- Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy.Cancer gene therapy · 2021Review
- Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy.Frontiers in genetics · 2021Review
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
DNA methylation plays an important role in regulating normal development and carcinogenesis. Current understanding of the biological roles of DNA methylation is limited to its role in the regulation of gene transcription, genomic imprinting, genomic stability, and X chromosome inactivation. In the past 2 decades, a large number of changes have been identified in cancer epigenomes when compared with normals. These alterations fall into two main categories, namely, hypermethylation of tumor suppressor genes and hypomethylation of oncogenes or heterochromatin, respectively. Aberrant methylation of genes controlling the cell cycle, proliferation, apoptosis, metastasis, drug resistance, and intracellular signaling has been identified in multiple cancer types. Recent advancements in whole-genome analysis of methylome have yielded numerous differentially methylated regions, the functions of which are largely unknown. With the development of high resolution tiling microarrays and high throughput DNA sequencing, more cancer methylomes will be profiled, facilitating the identification of new candidate genes or ncRNAs that are related to oncogenesis, new prognostic markers, and the discovery of new target genes for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.